Abstract:Diabetic kidney disease (DKD) is a global health problem and is an important risk factor for kidney failure and cardiovascular (CV) disease (Alicic et al., 2017). Until recently, renin angiotensin-aldosterone system inhibitors (RAASi) were the only available agents with proven renoprotective benefit (Brenner et al., 2001;Lewis et al., 2001). In 2019, sodium glucose co-transporter-2 inhibitors (SGLT-2i) revolutionized the management of DKD with added cardiovascular and renal benefits (Perkovic et al., 2019;Heerspink et al., 2020;EMPA-KIDNEY Collaborative Group, 2023). The last few years have been promising with the discovery of newer therapies in DKD targeting diverse pathophysiologic pathways (Heerspink et al., 2019;Bakris et al., 2020;Perkovic et al., 2024). Despite these existing therapies, there is a substantial residual risk of kidney disease progression (Figure 1).The pathogenesis of DKD, though initiated by a metabolic disturbance is perpetuated by multiple interlinked pathways involving the hemodynamic, inflammatory, oxidative, and fibrotic systems (Tuttle et al., 2022). This Research Topic aims to understand these complex mechanisms, identify newer therapeutic targets, and test these agents in well designed clinical trials. Eight articles were published in this Research Topic [retrospective studies (2), animal studies (2), meta-analysis (2), clinical trial (1), and in-depth review (1)]. The in-depth review by Zhang et al., summarizes the proposed mechanisms of albuminuria, the current progress, and the future directions of therapeutic avenues in DKD.Current practice guidelines recommend withholding SGLT-2i during critical illness requiring hospitalization ("sick day rules") (Watson et al., 2023). However, in a multicenter retrospective cohort study of adults hospitalized with acute heart failure associated AKI, exposure to SGLT-2i during AKI was associated with no difference in time to renal recovery, but a lower 30-day mortality (Aklilu et al., 2023). Whether these findings can be generalized to all other etiologies of AKI is unknown. In this Research Topic, Alcantar-Vallin et al. explore the role of continuing or initiating SGLT-2i during an AKI episode. This was a retrospective cohort study involving 374 patients hospitalized with AKI, of whom 58 received SGLT-2i treatment during the hospitalization. The authors found that SGLT-2i use was not associated with risk of major adverse kidney events but was associated with a reduced risk of mortality (OR 0.08, 95% CI 0.01-0.64).In the FLOW trial, semaglutide, a glucagon like peptide-1 receptor agonist (GLP-1Ra) was shown to decrease clinically relevant kidney outcomes and death from CV causes in patients with type 2 diabetes and CKD (Perkovic et al., 2024). In a post hoc analysis of this trial, the benefits of semaglutide in reducing kidney outcomes were found to be consistent in participants with and without SGLT-2i use (Mann et al., 2024). In this Research Topic Cao et al. carried out a head-to-head comparison of GLP-1Ra and SGLT-2i in patients with DKD. This was a randomized, open-label, non-inferiority trial. A total of 106 patients with type 2 diabetes and CKD were randomized 1:1 to receive either polyethylene glycol loxenatide (PEG-Loxe) 0.2 mg subcutaneous once weekly or dapagliflozin 10 mg orally once daily for 24 weeks. The primary outcome was change in urine albumin creatinine ratio (UACR) from baseline to 24 weeks. The authors showed that following 24 weeks of treatment there was no difference in change in UACR between the two groups (mean intergroup difference 1.7% (95% CI, -3 to 6.5%, p=0.380).Diabetes is a state of oxidative stress and inflammatory burden, which contributes to complications including diabetic nephropathy. The heightened oxidative stress in diabetes is multi-factorial, viz., activation of polyol and hexosamine pathways, accumulation of glycolysis intermediates, activation of protein kinase C, mitochondrial dysfunction, etc. (Jin et al., 2023). There is a strong mutually enhancing interaction between inflammation and oxidative stress. Pro-inflammatory cytokines and chemokines activate reactive oxygen species (ROS) leading to macrophage activation, resulting in more oxidative stress. In return, ROS induce the expression of pro-inflammatory cytokines by activating transcription factors like nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1) (Caturano et al., 2023). Hence addressing oxidative stress and inflammation as potential therapeutic targets for DKD have assumed greater significance (Winiarska et al., 2021). In recent years, Chinese herbal medicines have been reported to attenuate progression of DKD by their anti-inflammatory and anti-oxidative properties (Zhong et al., 2015). Chen et al. identified 16 potentially renoprotective Chinese herbal medicines for DKD (PRCHMDKD) which were known to target multiple oxidative stress pathways. The authors then retrospec -Abstract Truncated-

Translation Animal Models of Diabetic Kidney Disease: Biochemical and Histological Phenotypes, Advantages and Limitations

Kidney Disease Models: Tools to Identify Mechanisms and Potential Therapeutic Targets

Dynamic Phenotypes and Molecular Mechanisms to Understand the Pathogenesis of Diabetic Nephropathy in Two Widely Used Animal Models of Type 2 Diabetes Mellitus

Application of Animal Models in Diabetic Cardiomyopathy

Recent Advances in Animal Models of Diabetic Nephropathy

Animal Models of Kidney Disease: Challenges and Perspectives

Diabetic Kidney Disease: Challenges, Advances, And Opportunities

Modelling diabetic nephropathy in mice

Decoding the Intercellular Cross-Talking Between Immune Cells and Renal Innate Cells in Diabetic Kidney Disease by Bioinformatics

Design of Machine Learning Algorithms and Internal Validation of a Kidney Risk Prediction Model for Type 2 Diabetes Mellitus

Advances in Murine Models of Diabetic Nephropathy

Rodent models of diabetic nephropathy: their utility and limitations

Advances in Understanding Diabetic Kidney Disease Progression and the Mechanisms of Acupuncture Intervention

Identification of Novel Key Molecular Signatures in the Pathogenesis of Experimental Diabetic Kidney Disease

Mouse Models for Studying Diabetic Nephropathy

[Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review].

TFAM and Mitochondrial Protection in Diabetic Kidney Disease

Animal models for type 1 and type 2 diabetes: advantages and limitations

Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease

What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics